Phase II/III Randomized, Placebo-controlled Trial of Arimoclomol in SOD1 Positive Familial Amyotrophic Lateral Sclerosis

• Register: ClinicalTrials.gov
• Last refreshed on: 12 December 2020
• Main ID: NCT00706147
• Date of registration: 24/06/2008
• Prospective Registration: Yes
• Primary sponsor: University of Miami
• Public title: Phase II/III Randomized, Placebo-controlled Trial of Arimoclomol in SOD1 Positive Familial Amyotrophic Lateral Sclerosis
• Scientific title: Phase II/III Randomized, Placebo-Controlled Trial of Arimoclomol in SOD1 Positive Familial Amyotrophic Lateral Sclerosis (ALS)
• Date of first enrolment: January 2009
• Target sample size: 38
• Recruitment status: Completed
• URL: https://clinicaltrials.gov/show/NCT00706147
• Study type: Interventional
• Study design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Investigator).
• Phase: Phase 2/Phase 3

Countries of recruitment

United States

Contacts

• Name: Michael Benatar, MBChB, DPhil
• Affiliation: University of Miami

• Name: Merit Cudkowicz, MD, MSc
• Affiliation: Massachusetts General Hospital

Key inclusion & exclusion criteria

Inclusion Criteria:

- Type of ALS that is hereditary (runs in families) only.

- El Escorial criteria for familial ALS and a family history of a pathogenic mutation in
a gene known to be associated with ALS, such as the SOD1 gene.

- Willingness to undergo genetic testing and to learn the results.

- Demonstrable mutation in the SOD1 gene that is reported to be associated with a rapid
rate of disease progression (i.e. A4V, A4T, C6F, C6G, V7E, L8Q, G10V, G41S, H43R,
H48Q, D90V, G93A, D101H, D101Y, L106V, I112M, I112T, R115G, L126X, G127X, A145T,
V148G, V148I) or possibly associated with rapidly progressive disease (E21G, G37R,
L38V, D76Y, L84F, L84V, N86S, D90A het, G93R, I104F, I113T, L144F, L144S).

- Age 18 years or older; male or female.

- Capable of providing informed consent and complying with trial procedures.

- Diagnosis within less than 9 months of the anticipated date of the baseline visit AND
study participants' subjective evaluation that they expect their physical condition to
permit travel to the study site for both the baseline and 2-month study visits.

- Women must not be able to become pregnant (e.g. post menopausal for at least one year,
surgically sterile, or practicing adequate birth control methods) for the duration of
the study. Adequate contraception includes: oral contraception, implanted
contraception, intrauterine device in place for at least 3 months, or barrier method
in conjunction with spermicide.

- Women of childbearing potential must have a negative pregnancy test at screening visit
and be non-lactating.

- Willing to remain on a stable dose of Riluzole or to remain off Riluzole for the
duration of the trial.

- Identifiable local medical doctor to assist with urgent care of any medical
complications that may arise.

- Absence of any of the exclusion criteria.

Exclusion Criteria:

- History of known sensitivity or intolerability to Arimoclomol or to any other related
compound.

- Exposure to any investigational drug within 30 days of the screening visit.

- Presence of any of the following clinical conditions:

- Substance abuse within the past year.

- Unstable cardiac, pulmonary, renal, hepatic, endocrine, hematologic, or active
infectious disease.

- AIDS or AIDS-related complex.

- Unstable psychiatric illness defined as psychosis (hallucinations or delusions),
untreated major depression within 90 days of the screening visit.

- Positive pregnancy test at screening visit.

- Screening laboratory values:

- Creatinine greater than 1.5.

- Alanine aminotransferase (ALT) or Aspartate aminotransferase (AST). greater than
3.0 times the upper limit of normal.

- Total bilirubin greater than 2.0 times the upper limit of normal.

- White blood cell (WBC) count less than 3,500/mm3.

- Platelet concentration less than 100,000/ul.

- Hematocrit level less than 33 for female or less than 35 for male.

- Female patients who are breast-feeding.



Age minimum: 18 Years
Age maximum: N/A
Gender: All

Health Condition(s) or Problem(s) studied

Amyotrophic Lateral Sclerosis

Intervention(s)

Drug: Arimoclomol

Drug: Placebo

Primary Outcome(s)

Time to death, tracheostomy or permanent assisted ventilation will be the primary outcome measure. [Time Frame: 12 months]

Secondary Outcome(s)

Rate of decline of ALSFRS-R (ALS functional rating scale-revised) over a period of up to 12 months. [Time Frame: 12 months]

Safety and tolerability of arimoclomol will be evaluated by using vital signs and weight, clinical laboratory measures, physical examination, report of adverse events, and the proportion of subjects completing the study on assigned treatment. [Time Frame: 12 months]

Disease progression as measured by the rate of decline of FEV6. [Time Frame: 12 months]

Secondary ID(s)

3517

20100758

Source(s) of Monetary Support

Please refer to primary and secondary sponsors

Secondary Sponsor(s)

Massachusetts General Hospital